This innovative therapy has demonstrated remarkable success in hematological malignancies, such as leukemias and lymphomas, with FDA-approved therapies like Tisagenlecleucel and Axicabtagene ciloleucel targeting CD19, and Idecabtagene Vicleucel and Ciltacabtagene Autoleucel targeting B cell maturation antigen (BCMA) [5, 6]. This evidence concerns the gene TNFRSF17 and hematologic disorder.